share_log

Retail Investors Who Hold 55% of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Gained 6.5%, Insiders Profited as Well

浙江ジョリー製薬株式会社(SZSE:300181)の55%を保有する小売投資家は6.5%を獲得し、インサイダーも利益を上げました。

Simply Wall St ·  07/01 19:34

Key Insights

  • Zhejiang Jolly PharmaceuticalLTD's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public
  • 43% of the business is held by the top 25 shareholders
  • Insider ownership in Zhejiang Jolly PharmaceuticalLTD is 24%

A look at the shareholders of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) can tell us which group is most powerful. The group holding the most number of shares in the company, around 55% to be precise, is retail investors. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

Retail investors gained the most after market cap touched CN¥11b last week, while insiders who own 24% also benefitted.

In the chart below, we zoom in on the different ownership groups of Zhejiang Jolly PharmaceuticalLTD.

ownership-breakdown
SZSE:300181 Ownership Breakdown July 1st 2024

What Does The Institutional Ownership Tell Us About Zhejiang Jolly PharmaceuticalLTD?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

As you can see, institutional investors have a fair amount of stake in Zhejiang Jolly PharmaceuticalLTD. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Zhejiang Jolly PharmaceuticalLTD's historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
SZSE:300181 Earnings and Revenue Growth July 1st 2024

Hedge funds don't have many shares in Zhejiang Jolly PharmaceuticalLTD. Looking at our data, we can see that the largest shareholder is Youqiang Yu with 19% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 3.2% and 2.4%, of the shares outstanding, respectively.

Our studies suggest that the top 25 shareholders collectively control less than half of the company's shares, meaning that the company's shares are widely disseminated and there is no dominant shareholder.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

Insider Ownership Of Zhejiang Jolly PharmaceuticalLTD

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Our information suggests that insiders maintain a significant holding in Zhejiang Jolly Pharmaceutical Co.,LTD. It is very interesting to see that insiders have a meaningful CN¥2.7b stake in this CN¥11b business. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling.

General Public Ownership

The general public, who are usually individual investors, hold a substantial 55% stake in Zhejiang Jolly PharmaceuticalLTD, suggesting it is a fairly popular stock. With this amount of ownership, retail investors can collectively play a role in decisions that affect shareholder returns, such as dividend policies and the appointment of directors. They can also exercise the power to vote on acquisitions or mergers that may not improve profitability.

Private Company Ownership

We can see that Private Companies own 4.3%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Be aware that Zhejiang Jolly PharmaceuticalLTD is showing 1 warning sign in our investment analysis , you should know about...

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする